PUBLISHER: The Business Research Company | PRODUCT CODE: 1942582
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942582
Cold allergy and sinus tablets are over-the-counter or prescription medications formulated to relieve symptoms related to colds, allergies, and sinus conditions. These tablets typically combine antihistamines, decongestants, and pain relievers to reduce inflammation, congestion, and discomfort caused by these conditions.
The main types of cold allergy and sinus tablets include antihistamines, decongestants, cough suppressants, expectorants, and combination tablets. Antihistamines are medications that block or reduce the effects of histamines, chemicals released by the immune system during allergic reactions. These products are available in various formulations, including tablets, capsules, liquids, effervescent tablets, and powders. The consumer age groups vary from children (0-12 years) to teenagers (13-19 years), adults (20-64 years), and seniors (65 years and above). These products address multiple conditions, such as allergic rhinitis, the common cold, sinusitis, and more. Distribution occurs through several channels, including pharmacies, online stores, supermarkets or hypermarkets, and others.
Tariffs are impacting the cold allergy and sinus tablet market by increasing the cost of imported active pharmaceutical ingredients, excipients, packaging materials, and specialized manufacturing inputs used in antihistamines, decongestants, and combination tablets. North America and Europe are particularly affected due to dependence on imported APIs from Asia-Pacific manufacturing hubs such as China and India. These tariffs are contributing to higher production costs and pricing pressures for branded and generic products. However, they are also encouraging local API manufacturing, diversification of sourcing strategies, and increased investments in domestic pharmaceutical production capabilities.
The cold allergy and sinus tablet market research report is one of a series of new reports from The Business Research Company that provides cold allergy and sinus tablet market statistics, including cold allergy and sinus tablet industry global market size, regional shares, competitors with a cold allergy and sinus tablet market share, detailed cold allergy and sinus tablet market segments, market trends and opportunities, and any further data you may need to thrive in the cold allergy and sinus tablet industry. This cold allergy and sinus tablet market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cold allergy and sinus tablet market size has grown strongly in recent years. It will grow from $30.4 billion in 2025 to $32 billion in 2026 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to rising prevalence of allergic rhinitis, increased seasonal cold incidences, widespread availability of OTC medications, growth of self-medication practices, established pharmaceutical retail networks.
The cold allergy and sinus tablet market size is expected to see strong growth in the next few years. It will grow to $39.08 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to growing urban pollution exposure, increasing consumer preference for combination therapies, rising demand for allergy management solutions, expansion of online pharmacy distribution, continuous product reformulation innovation. Major trends in the forecast period include increasing demand for multi-symptom combination tablets, rising preference for non-drowsy formulations, growing focus on fast-acting relief solutions, expansion of age-specific dosage variants, enhanced emphasis on extended-release tablets.
The increasing incidence of allergies and respiratory disorders is projected to drive growth in the cold allergy and sinus tablet market in the years ahead. These conditions involve immune system responses to allergens and affect the respiratory system, leading to illnesses such as asthma and allergic rhinitis. The surge in allergies and respiratory issues is largely linked to rising air pollution, which heightens exposure to allergens and airborne irritants that trigger adverse immune and respiratory reactions. Cold allergy and sinus tablets assist in managing these conditions by providing effective symptom relief, thereby enhancing the quality of life for individuals suffering from colds, sinus infections, and allergic reactions. For example, in September 2023, the World Health Organization, an intergovernmental agency based in Switzerland, reported that chronic respiratory diseases were responsible for 4.1 million deaths, ranking behind cardiovascular disease (17.9 million deaths) and cancer (9.3 million deaths), and ahead of diabetes (2.0 million deaths). Thus, the rising prevalence of respiratory and allergic conditions is fueling demand in the cold allergy and sinus tablet market.
Major companies operating in the cold, allergy, and sinus tablet market are focusing on developing innovative fixed-dose combination (FDC) formulations that incorporate multiple active ingredients into a single tablet to enhance treatment convenience, provide broader symptom relief, and reduce the need for multiple medications. An FDC combines complementary agents-such as an analgesic or antipyretic, a nasal decongestant, and an antihistamine-to deliver integrated relief for cold, allergy, and sinus symptoms compared with traditional single-ingredient tablets. For example, in April 2025, Johnson & Johnson, a U.S.-based pharmaceutical and consumer health products company, launched Sinumax Allergy Sinus Caplets for short-term relief of cold, allergy, and sinus discomfort. The caplets contain paracetamol 500 mg, pseudoephedrine hydrochloride 30 mg, and chlorphenamine maleate 2 mg, addressing nasal congestion, headache, fever, sneezing, and runny nose. Its sugar-free film coating, immediate-release formulation, and non-sedating antihistamine component enhance user comfort and ease of administration.
In April 2025, Clayton, Dubilier & Rice (CD&R), a U.S.-based private equity firm, acquired a 50% controlling stake in Opella from Sanofi S.A. for an undisclosed amount. This transaction aligns with Sanofi's strategy to concentrate on its core innovative medicines and vaccines portfolio while allowing Opella to operate as an independent global consumer health leader with increased investment and growth potential. Opella is a France-based company that manufactures over-the-counter (OTC) products, including cold, allergy, pain relief, digestive health, and wellness brands.
Major companies operating in the cold allergy and sinus tablet market are Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline plc, Reckitt Benckiser Group plc, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Dr. Reddy's Laboratories, Cipla Limited, Hikma Pharmaceuticals plc, Lupin Ltd., Glenmark Pharmaceuticals Ltd., LETI Pharma GmbH, Pfizer Inc., Novartis AG, Haleon Group plc, Perrigo Consumer Healthcare, Zydus Lifesciences Ltd.
North America was the largest region in the cold allergy and sinus tablet market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cold allergy and sinus tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the cold allergy and sinus tablet market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The cold allergy and sinus tablet market consists of sales of allerhin cold tablet, sinarest tablet, and allergix cold care tablet. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cold Allergy And Sinus Tablet Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses cold allergy and sinus tablet market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for cold allergy and sinus tablet ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cold allergy and sinus tablet market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.